Publications by authors named "Saki Egashira"
Monoclonal Antibody Rat 2F11 and Rabbit A3 Against Anti-H2b3b.
Monoclon Antib Immunodiagn Immunother
April 2024
Production of a Monoclonal Antibody for Histone H2b Isoform H2b3b.
Monoclon Antib Immunodiagn Immunother
April 2024
H2b3b is one of the histone H2b isoforms that differs from canonical H2b by five to six amino acids. Previously, we identified H3t as the testis-specific histone H3 variant located in histone cluster 3, which is also the site of H2b3b. In this study, we produced monoclonal antibodies against H2b3b, using the iliac rat lymph node method for rat antibody and the immunochamber method for rabbit antibody.
View Article and Find Full Text PDFArticle Synopsis
- The study explores the risks of delayed tPA treatment for ischemic stroke, which can lead to intracerebral hemorrhage, and introduces the use of an anti-high mobility group box 1 (αHMGB1) antibody as a potential alternative.
- In experiments with a 4-hour MCAO mouse model, αHMGB1 treatment showed reduced infarct volume, brain swelling, and neurologic impairment without causing hemorrhagic complications, unlike tPA.
- The findings suggest that αHMGB1 could be a beneficial therapy for stroke patients beyond the time limits set for tPA administration, by inhibiting inflammation and reducing brain damage.
Article Synopsis
- HMGB1 is a protein that worsens outcomes after brain ischemia, while haptoglobin (Hp) can bind to it and help mitigate its negative effects.
- In a study involving mice, administering Hp after inducing ischemia showed improvements in neurological function, motor coordination, and reduced brain damage over time.
- Hp was found to decrease HMGB1 levels and favor the M2 macrophage/microglia phenotype, suggesting it may be a promising treatment for cerebral ischemia recovery.